ArticleJTO clinical and research reports2024
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance.
Malinda Itchins et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.